O	0	1	A
O	2	8	double
O	8	9	-
O	9	14	blind
O	15	22	placebo
O	22	23	-
O	23	33	controlled
O	34	39	study
O	40	42	to
O	43	51	evaluate
B-condition	52	63	endometrial
I-condition	64	70	safety
I-condition	71	74	and
I-condition	75	89	gynaecological
I-condition	90	98	symptoms
O	99	101	in
O	102	107	women
O	108	115	treated
O	116	119	for
O	120	122	up
O	123	125	to
O	126	127	5
O	128	133	years
O	134	138	with
B-intervention	139	148	tamoxifen
O	149	151	or
B-control	152	159	placebo
O	160	161	-
O	162	163	a
O	164	172	substudy
O	173	176	for
O	177	181	IBIS
O	182	183	I
O	184	190	Breast
O	191	197	Cancer
O	198	208	Prevention
O	209	214	Trial
O	214	215	.

O	216	220	This
O	221	232	prospective
O	233	238	study
O	239	242	was
O	243	252	performed
O	253	255	to
O	256	267	investigate
O	268	271	the
O	272	279	effects
O	280	282	of
O	283	284	5
O	284	285	-
O	285	289	year
O	289	290	'
O	290	291	s
O	292	295	use
O	296	298	of
O	299	308	tamoxifen
O	309	311	in
O	312	322	preventive
O	323	330	setting
O	331	333	on
O	334	345	endometrium
O	346	349	and
O	350	364	gynaecological
O	365	373	symptoms
O	373	374	.

O	375	385	Altogether
B-total-participants	386	388	96
O	389	394	women
O	395	399	were
O	400	407	treated
O	408	414	either
O	415	419	with
O	420	429	tamoxifen
O	430	431	(
O	431	434	TAM
O	434	435	,
O	436	437	n
O	437	438	=
B-intervention-participants	438	440	45
O	440	441	)
O	442	444	or
B-control	445	452	placebo
O	453	454	(
O	454	457	PLA
O	457	458	,
O	459	460	n
O	460	461	=
B-control-participants	461	463	51
O	463	464	)
O	465	468	for
O	469	471	up
O	472	474	to
O	475	476	5
O	477	482	years
O	483	485	in
O	486	487	a
O	488	498	randomised
O	498	499	,
O	500	506	double
O	506	507	-
O	507	512	blind
O	513	517	IBIS
O	518	519	I
O	520	526	breast
O	527	533	cancer
O	534	544	prevention
O	545	550	trial
O	550	551	,
O	552	562	clinically
O	563	571	followed
O	571	572	-
O	572	574	up
O	575	578	for
O	579	581	an
O	582	592	additional
O	593	597	year
O	598	601	and
O	602	605	for
O	606	609	the
O	610	620	occurrence
O	621	623	of
O	624	636	malignancies
O	637	639	at
O	640	645	least
O	646	647	9
O	648	653	years
O	654	661	between
O	662	663	2
O	663	664	/
O	664	668	1995
O	669	672	and
O	673	674	7
O	674	675	/
O	675	679	2009
O	680	682	in
B-location	683	690	Finland
O	690	691	.

O	692	695	The
O	696	710	gynaecological
O	711	717	follow
O	717	718	-
O	718	720	up
O	721	725	with
O	726	731	trans
O	731	732	-
O	732	739	vaginal
O	740	750	ultrasound
O	751	754	and
O	755	766	endometrial
O	767	775	biopsies
O	776	780	were
O	781	790	performed
O	791	793	at
O	794	802	baseline
O	802	803	,
O	804	806	at
O	807	808	2
O	808	809	.
O	809	810	5
O	811	814	and
O	815	816	5
O	817	822	years
O	823	826	and
O	827	829	at
O	830	833	the
O	834	835	6
O	836	841	years
O	842	848	follow
O	848	849	-
O	849	851	up
O	852	857	visit
O	857	858	.

O	859	864	Women
O	865	867	in
O	868	871	the
O	872	875	TAM
O	876	881	group
B-outcome	882	894	discontinued
I-outcome	895	898	the
I-outcome	899	908	treatment
O	909	922	significantly
O	923	927	more
O	928	933	often
O	934	935	(
B-iv-bin-percent	935	937	44
I-iv-bin-percent	937	938	%
O	939	945	versus
B-cv-bin-percent	946	948	22
I-cv-bin-percent	948	949	%
O	949	950	;
O	951	952	p
O	952	953	=
O	953	954	0
O	954	955	.
O	955	958	017
O	958	959	)
O	960	963	and
O	964	971	earlier
O	972	973	(
O	973	975	at
B-iv-cont-median	976	978	15
O	979	985	versus
B-cv-cont-median	986	988	30
I-cv-cont-median	989	995	months
O	995	996	;
O	997	998	p
O	998	999	=
O	999	1000	0
O	1000	1001	.
O	1001	1004	044
O	1004	1005	)
O	1005	1006	,
O	1007	1011	than
O	1012	1017	those
O	1018	1020	in
O	1021	1024	the
O	1025	1028	PLA
O	1029	1034	group
O	1034	1035	.

O	1036	1038	In
O	1039	1053	postmenopausal
O	1054	1059	women
O	1060	1063	the
O	1064	1070	median
B-outcome	1071	1082	endometrial
I-outcome	1083	1092	thickness
O	1093	1096	was
O	1097	1110	significantly
O	1111	1120	increased
O	1121	1123	at
O	1124	1128	five
O	1129	1134	years
O	1135	1137	in
O	1138	1141	the
O	1142	1145	TAM
O	1146	1151	group
O	1152	1153	(
O	1153	1159	median
B-iv-cont-median	1160	1161	4
I-iv-cont-median	1161	1162	.
I-iv-cont-median	1162	1163	3
O	1164	1170	versus
B-cv-cont-median	1171	1172	2
I-cv-cont-median	1172	1173	.
I-cv-cont-median	1173	1176	0mm
O	1176	1177	,
O	1178	1179	p
O	1179	1180	=
O	1180	1181	0
O	1181	1182	.
O	1182	1185	011
O	1185	1186	)
O	1186	1187	,
O	1188	1191	but
O	1192	1197	there
O	1198	1201	was
O	1202	1204	no
O	1205	1215	difference
O	1216	1223	between
O	1224	1227	the
O	1228	1234	groups
O	1235	1237	at
O	1238	1241	one
O	1242	1246	year
O	1247	1252	after
O	1253	1256	the
O	1257	1266	treatment
O	1266	1267	.

O	1268	1273	There
O	1274	1278	were
O	1279	1283	also
O	1284	1297	statistically
O	1298	1311	significantly
O	1312	1316	more
B-outcome	1317	1326	referrals
I-outcome	1327	1329	to
I-outcome	1330	1339	hospitals
I-outcome	1340	1343	due
I-outcome	1344	1346	to
I-outcome	1347	1361	gynaecological
I-outcome	1362	1370	findings
O	1371	1373	in
O	1374	1377	the
O	1378	1381	TAM
O	1382	1387	group
O	1388	1389	(
O	1389	1393	risk
O	1394	1399	rates
O	1400	1401	(
O	1401	1403	RR
O	1403	1404	)
O	1405	1406	3
O	1406	1407	.
O	1407	1409	15
O	1409	1410	;
O	1411	1413	95
O	1413	1414	%
O	1415	1425	confidence
O	1426	1435	intervals
O	1436	1437	(
O	1437	1439	CI
O	1439	1440	)
O	1441	1442	1
O	1442	1443	.
O	1443	1445	12
O	1445	1446	-
O	1446	1448	10
O	1448	1449	.
O	1449	1451	10
O	1451	1452	)
O	1452	1453	,
O	1454	1457	but
O	1458	1460	no
O	1461	1472	differences
O	1473	1475	in
B-outcome	1476	1488	hysterectomy
I-outcome	1489	1494	rates
O	1495	1497	or
O	1498	1503	other
B-outcome	1504	1511	serious
I-outcome	1512	1519	adverse
I-outcome	1520	1525	event
I-outcome	1526	1531	rates
O	1532	1536	were
O	1537	1545	observed
O	1545	1546	.

O	1547	1550	The
B-outcome	1551	1566	discontinuation
I-outcome	1567	1571	rate
O	1572	1574	in
O	1575	1578	the
O	1579	1582	TAM
O	1583	1588	group
O	1589	1592	was
O	1593	1597	high
O	1597	1598	,
O	1599	1602	and
O	1603	1606	the
O	1607	1623	discontinuations
O	1624	1628	also
O	1629	1637	occurred
O	1638	1643	early
O	1643	1644	.

O	1645	1649	Even
O	1650	1656	though
O	1657	1662	there
O	1663	1667	were
O	1668	1681	significantly
O	1682	1686	more
O	1687	1690	non
O	1690	1691	-
O	1691	1698	serious
O	1699	1713	gynaecological
O	1714	1720	events
O	1721	1727	during
O	1728	1731	the
O	1732	1735	TAM
O	1736	1745	treatment
O	1745	1746	,
O	1747	1754	routine
O	1755	1769	gynaecological
O	1770	1776	follow
O	1776	1777	-
O	1777	1779	up
O	1780	1786	cannot
O	1787	1789	be
O	1790	1801	recommended
O	1801	1802	.
